A Phase I/II Trial of Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib.
Phase of Trial: Phase I/II
Latest Information Update: 05 May 2015
At a glance
- Drugs Cetuximab; Erlotinib
- Indications Lung cancer
- Focus Adverse reactions; Therapeutic Use
- 25 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 25 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.